Richard Hermann, MD

AstraZeneca

Poster(s):

• 1522 - MAVRiC: A Phase 2 Study of Mutation-Guided Finite-Duration Acalabrutinib Plus Venetoclax for Relapse After Frontline Finite-Duration Covalent Bruton Tyrosine Kinase Inhibitor Plus Venetoclax‒Based Combination Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma